Study discovers enzyme that may prevent streptococci infection
Researchers have found an enzyme that could prevent a deadly streptococci infection that causes around 500,000 deaths worldwide each year.
Group A streptococcus can lead to illnesses such a s strep throat, scarlet fever, sepsis, and toxic shock syndrome as well as several long-term autoimmune diseases with high mortality rates.
Working with colleagues, the researchers found an enzyme that is required to produce a carbohydrate on the surface of the streptococcal bacterium which enables it to infect humans and animals.
Their research reveals new opportunities to inhibit this enzyme and ultimately, fight Group A Streptococcus infections.
The fact this enzyme works through a novel mechanism of action that can also be found in other streptococcal species increases the impact and relevance of this finding.
Strep throat is the most common Group A Streptococcus infection and can often be fought by the body's immune system. Unfortunately, the very same bacterium also causes a plethora of severe and potentially fatal illnesses, such as sepsis and toxic shock syndrome, said one of the researcher.
We knew that the carbohydrate coating was an essential component of Group A Strep, but we wanted to find out more about how this worked. What we've shown is that the enzyme initiates the synthesis of the bacterial coating, continued the Dr.
Surprisingly, we also found that this enzyme fulfills the same function in many other types of streptococci. This includes Group B Streptococci, that can cause severe infections in newborns, and Group C and G Streptococci that cause similar disease as Group A, including bacteraemia and endocarditis, in humans and animals, added the Dr.
The newly discovered enzyme is not present in humans or animals, therefore providing a novel,opportunity for drug discovery programmes, reported the study published recently.
Antimicrobial resistance is a global problem and existing antibiotics fail to work in around 20 % of cases of strep throat. The long term aim of the Dundee team is to aid the development of a new class of antimicrobial drugs that could completely inhibit or reduce the enzyme's activity.
The next step towards this goal will see them work with others to develop compounds that could target this enzyme.
The research was jointly led by PhD student and another researcher explained, in our study, we show how this protein initiates the production of this carbohydrate through a mechanism never described before.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
Group A streptococcus can lead to illnesses such a s strep throat, scarlet fever, sepsis, and toxic shock syndrome as well as several long-term autoimmune diseases with high mortality rates.
Working with colleagues, the researchers found an enzyme that is required to produce a carbohydrate on the surface of the streptococcal bacterium which enables it to infect humans and animals.
Their research reveals new opportunities to inhibit this enzyme and ultimately, fight Group A Streptococcus infections.
The fact this enzyme works through a novel mechanism of action that can also be found in other streptococcal species increases the impact and relevance of this finding.
Strep throat is the most common Group A Streptococcus infection and can often be fought by the body's immune system. Unfortunately, the very same bacterium also causes a plethora of severe and potentially fatal illnesses, such as sepsis and toxic shock syndrome, said one of the researcher.
We knew that the carbohydrate coating was an essential component of Group A Strep, but we wanted to find out more about how this worked. What we've shown is that the enzyme initiates the synthesis of the bacterial coating, continued the Dr.
Surprisingly, we also found that this enzyme fulfills the same function in many other types of streptococci. This includes Group B Streptococci, that can cause severe infections in newborns, and Group C and G Streptococci that cause similar disease as Group A, including bacteraemia and endocarditis, in humans and animals, added the Dr.
The newly discovered enzyme is not present in humans or animals, therefore providing a novel,opportunity for drug discovery programmes, reported the study published recently.
Antimicrobial resistance is a global problem and existing antibiotics fail to work in around 20 % of cases of strep throat. The long term aim of the Dundee team is to aid the development of a new class of antimicrobial drugs that could completely inhibit or reduce the enzyme's activity.
The next step towards this goal will see them work with others to develop compounds that could target this enzyme.
The research was jointly led by PhD student and another researcher explained, in our study, we show how this protein initiates the production of this carbohydrate through a mechanism never described before.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
Labels: antimicrobial resistance, autoimmune diseases, enzyme, high mortality, infections, prevent, sepsis, streptococcus, toxic shock syndrome
posted by G S Iyer at 3:51 AM
0 Comments:
Post a Comment
<< Home